> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lexicon Pharma Fast Track for Neuropathic Pain
- URL: https://www.fdaweb.com/lexicon-pharma-fast-track-for-neuropathic-pain/
- Published: 2020-12-11T12:00:00.000Z
- Updated: 2026-09-14T16:39:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148286

FDA has granted Lexicon Pharmaceuticals a fast track designation for LX9211 and its use in treating diabetic peripheral neuropathic pain. The company says it is currently enrolling patients with this condition in a Phase 2 proof-of-concept study and it is preparing to initiate a second Phase 2 clinical trial in post-herpetic neuralgia.

LX9211 is described as a potent, orally delivered, selective small molecule inhibitor of adapter-associated kinase 1\. Preclinical studies involving the drug have demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways, it says.